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Background
M e t a b o l i cs y n d r o m ei sa ni m p o r t a n ts i d ee f f e c ta s s o -
ciated with clozapine. It has been hypothesized that
weight gain contributes to the development of metabolic
syndrome, but a direct diabetogenetic effect has also
been suggested. We conducted an 8-year cohort study
to determine the association between weight gain and
metabolic parameters among schizophrenic patients on
clozapine.
Materials and methods
The subjects were hospitalized schizophrenic patients
who began to receive clozapine and subsequently had
monthly body weight monitoring during the entire study
period. Chart reviews were conducted to obtain gender,
age at initiation of clozapine treatment, baseline Body
Mass Index (BMI), BMI changes after the initiation of
clozapine treatment, treatment duration with clozapine
and concomitant psychotropic medications. Anthropo-
metric and biochemical measurements were performed
to determine the presence of metabolic syndrome.
Results
Patients were maintained on clozapine for an average
treatment duration of 56.0 ± 27.8 (range 5 to 96)
months. The prevalence of metabolic syndrome was
28.7%. The cohort regression models showed that base-
line BMI (p < 0.0001) and BMI change after clozapine
treatment (p < 0.0001) were significant factors for meta-
bolic syndrome as were most metabolic parameters
except hyperglycemia and diabetes mellitus, which were
related to treatment duration (p < 0.05).
Conclusions
For patients treated with clozapine, metabolic syndrome
and most metabolic parameters were related to weight
gain; however, glucose dysregulation was associated with
treatment duration independent of weight gain. The
results confirm that monitoring body weight is impor-
tant, but periodic monitoring of blood sugar may also
be required for clozapine patients who do not have sig-
nificant weight gain.
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